What's Happening?
Researchers at the University of Chicago have identified a mechanism that can reprogram immune cells, which are typically suppressed by radiation therapy, to instead attack tumors. Published in Cancer Cell, the study reveals that radiation activates a protein
called TET2 in bone marrow immune cells. This activation causes TET2 to remove chemical tags from RNA, locking these cells into an immune-suppressing state. When TET2 was blocked, these same cells began fighting cancer, enhancing the effectiveness of radiation and immunotherapy in shrinking tumors and controlling metastasis in mouse models. This discovery suggests that the immune-suppressing effects of radiation are not permanent and can be reversed, potentially leading to more effective cancer treatments. The team observed that patients with elevated TET2 levels after radiation treatment had poorer outcomes, reinforcing the idea that TET2 acts as a barrier to effective cancer therapy.
Why It's Important?
This research holds significant implications for cancer treatment, particularly for the 50% to 60% of cancer patients who undergo radiation therapy. Radiation, while effective in killing tumor cells, can inadvertently trigger the expansion of myeloid-derived suppressor cells (MDSCs), which hinder the body's immune response against cancer. By identifying TET2 as a key player in this immune suppression, and demonstrating that blocking it can convert MDSCs into tumor-fighting myeloid-derived activating cells (MDACs), the study opens new avenues for therapeutic intervention. This could lead to improved patient outcomes, reduced risk of metastasis, and enhanced responses to existing immunotherapies. The ability to reprogram these immune cells could transform how radiation therapy is administered, making it a more potent tool in the fight against various cancers, including non-small cell lung cancer, colon cancer, and melanoma.
What's Next?
The University of Chicago team is now exploring how TET2 inhibitors, which are experimental drugs, might be tested in combination with radiation therapy in human patients. Since gene deletion is not a viable option for patients, the focus is on pharmacological interventions that can achieve similar results. The findings suggest that targeting TET2 or the chromatin-associated RNAs it affects could prevent or treat metastasis. This research could pave the way for clinical trials to evaluate the efficacy and safety of TET2-blocking drugs in cancer patients. The upcoming AbbVie Foundation Cancer Pavilion at UChicago Medicine, set to open in April 2027, will provide a dedicated facility for advanced diagnostics, innovative treatments, and translational discoveries, potentially accelerating the development and implementation of such novel therapies.
Beyond the Headlines
The deeper implications of this research extend to understanding the complex interplay between radiation, the immune system, and cancer progression. The discovery that radiation resistance is a reversible program, rather than a fixed one, challenges previous assumptions and highlights the epigenetic machinery of immune cells as a critical target. This could lead to a paradigm shift in how cancer is treated, moving towards more personalized and adaptive therapies that not only target cancer cells directly but also manipulate the immune microenvironment to the patient's advantage. The identification of chromatin-associated RNAs as potential drug targets also opens up new avenues for drug discovery, potentially leading to a new class of therapeutics that can fine-tune immune responses and improve long-term survival for cancer patients.
